The Effect of Pneumococcal Polysaccharide Vaccine in a Mouse Model of Allergic Rhinitis

Abstract

Objectives

This study aimed to determine if pneumococcal polysaccharide vaccine (PPV) could suppress allergic inflammation in an allergic rhinitis mouse model and to explore whether differences exist regarding the effect of PPV according to timing of administration.

Study Design

In vivo study using an animal model.

Setting

Catholic Research Institutes of Medical Science.

Subjects and Methods

BALB/c mice were divided into control, Der f, Pre-S, and Post-S groups. The allergen was Dermatophagoides farinae (Der f). Pneumococcal polysaccharide vaccine was administered before (Pre-S) or after (Post-S) sensitization. Allergic symptoms and eosinophils in nasal mucosa, interferon-γ, interleukin (IL)–13, and IL-10 in nasal lavage fluid and serum Der f–specific IgE were measured. T-bet, GATA-3, and Foxp3 mRNA in spleen were determined by real-time polymerase chain reaction. Flow cytometry of CD4⁺CD25⁺Foxp3⁺ T cells in spleen was analyzed.

Results

In the Pre-S group, symptom score, serum Der f–specific IgE, eosinophils, IL-13, and GATA-3 mRNA were decreased (P < .05), and IL-10, Foxp3 mRNA, and CD4⁺CD25⁺Foxp3⁺ T cells were increased compared with those in Der f group (P < .05). In the Post-S group, symptom score, serum Der f–specific IgE, and GATA-3 mRNA were decreased (P < .05), and Foxp3 mRNA and CD4⁺CD25⁺Foxp3⁺ T cells were increased compared with those in the Der f group (P < .05).

Conclusion

These results suggest that PPV administered before or after sensitization suppresses Th2 response and enhanced induction of regulatory T cells in an allergic rhinitis model. In addition, there was no significant difference between the degrees of effects in these 2 conditions. In the future, we can consider PPV to be a preventative agent for allergic rhinitis.

Keywords

pneumococcal vaccine polysaccharide vaccine allergic rhinitis a mouse model regulatory T cells Th2 cells sensitization

Get full access to this article

View all access options for this article.

References

Bousquet

Khaltaev

Cruz

. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160.

Strachan

. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-1260.

Bartlett

Mundy

. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.

Pesek

Lockey

. Vaccination of adults with asthma and COPD. Allergy. 2011;66:25-31.

Obert

Burgel

. Pneumococcal infections: association with asthma and COPD. Med Mal Infect. 2012;42:188-192.

Bisgaard

Hermansen

Buchvald

. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357:1487-1495.

Talbot

Hartert

Mitchel

. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med. 2005;352:2082-2090.

Whitney

Farley

Hadler

. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.

Nuorti

JP.

Nuorti . Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol. 2012;175:827-837.

10.

Preston

Essilfie

Horvat

. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine. 2007;25:8154-8162.

11.

Thorburn

O’Sullivan

Thomas

. Pneumococcal conjugate vaccine–induced regulatory T cells suppress the development of allergic airways disease. Thorax. 2010;65:1053-1060.

12.

Cheng

Wen

. Inverse association between T-cell immunoglobulin and mucin domain-1 and T-bet in a mouse model of allergic rhinitis. Laryngoscope. 2007;117:960-964.

13.

San Román

Irache

Gómez

Gamazo

Espuelas

. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis. Int Arch Allergy Immunol. 2009;149:111-118.

14.

Klemets

Lyytikäinen

Ruutu

. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax. 2010;65:698-702.

15.

Jung

Kita

Yawn

. Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma. J Allergy Clin Immunol. 2010;125:217-221.

16.

Thorburn

Hansbro

Gibson

. Pneumococcal vaccines for allergic airways diseases. Expert Opin Biol Ther. 2009;9:621-629.

17.

Nuorti

Whitney

; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1-18.

18.

Musher

Manof

Liss

. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201:516-524.

19.

Ansaldi

Turello

Lai

. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res. 2005;33:490-500.

20.

Sheikh

Alves

Dhami

. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev. 2002;(1):CD002165.

21.

Preston

Thorburn

Starkey

. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur Respir J. 2011;37:53-64.

22.

Thorburn

Foster

Gibson

. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol. 2012;188:4611-4620.